Biotech major Amgen has announced that the US Food and Drug Administration (FDA) has accepted and granted Priority Review for the company's Biologics License Ap 14 December 2023
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.